Abstract
Osteonecrosis of the jaws is a major complication associated with long-term use of bisphosphonates. While osteonecrosis can arise from other precipitating conditions, bisphosphonate-induced jaw osteonecrosis (BJON) is highly associated with long-term administration of pamidronate (Aredia®) and zoledronic acid (Zometa®), which are two intravenous bisphosphonate formulations. The underlying pathogenesis of BJON and its site-specific presentation still remain to be fully elucidated. This review will discuss clinically available bisphosphonates, current opinions, pathogenesis, and management guidelines for bisphosphonate-induced jaw osteonecrosis.
Original language | English (US) |
---|---|
Pages (from-to) | 277-285 |
Number of pages | 9 |
Journal | Oral Diseases |
Volume | 14 |
Issue number | 3 |
DOIs | |
State | Published - Apr 2008 |
Externally published | Yes |
Keywords
- Biology
- Bisphosphonates
- Bone marrow
- Jaw
- Osteonecrosis
ASJC Scopus subject areas
- Otorhinolaryngology
- General Dentistry